Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 1 records in total 1
    records per page

    Clinical characteristics and outcomes in diabetes patients admitted with COVID-19 MESHD in Dubai: a cross-sectional single centre study.

    Authors: Rahila Bhatti; Amar Omer; Samara Khattib; Seemin Shiraz; Glenn Matfin

    doi:10.1101/2020.07.08.20149096 Date: 2020-07-10 Source: medRxiv

    Aim: To describe the clinical characteristics and outcomes of hospitalised Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) patients with diabetes MESHD. Methods: A cross-sectional observational study was conducted in patients with diabetes MESHD admitted with COVID-19 MESHD to Mediclinic Parkview Hospital in Dubai, United Arab Emirates (UAE) from 30th March to 7th June 2020. They had laboratory and/or radiologically confirmed severe acute respiratory syndrome-coronavirus-2 MESHD (SARS-CoV-2), known as COVID-19 MESHD. Variation in characteristics, length of stay in hospital, diabetes MESHD status, comorbidities and outcomes were examined. Results: A total of 103 patients with confirmed COVID-19 MESHD presentations had diabetes MESHD. During the same timeframe, 410 patients overall were admitted with COVID-19 MESHD infection. This gives a total proportion of persons admitted with COVID-19 MESHD infection and coexistent diabetes MESHD/prediabetes of 25%. 67% (n=69) of the COVID-19 MESHD diabetes MESHD cohort were male. Patients admitted with COVID-19 MESHD and diabetes MESHD represented 17 different ethnicities. Of these, 59.2% (n=61) were Asians and 35% (n=36) were from Arab countries. Mean age (SD) was 54 (12.5) years. 85.4% (n=88) were known to have diabetes MESHD prior to admission, while 14.6% (n=15) were newly diagnosed with either diabetes MESHD or prediabetes MESHD during admission. Most patients in the study cohort had type 2 diabetes MESHD or prediabetes MESHD, with only 3% overall having type 1 diabetes MESHD (n=3). 46.9% of patients had evidence of good glycaemic control of their diabetes MESHD during the preceding 4-12 weeks prior to admission as defined arbitrarily by admission HbA1 HGNCc <7.5%. 73.8% (n=76) had other comorbidities including hypertension MESHD, ischaemic heart disease MESHD, and dyslipidaemia. Laboratory data Mean(SD) on admission for those who needed ward-based care versus those needing intensive care unit (ICU) care: Fibrinogen HGNC 462.75 (125.16) mg/dl vs 660 (187.58) mg/dl ; D-dimer 0.66 (0.55) mcg/ml vs 2.3 (3.48) mcg/ml; Ferritin 358.08 (442.05) mg/dl vs 1762.38 (2586.38) mg/dl; and CRP HGNC 33.9 (38.62) mg/L vs 137 (111.72) mg/L were all statistically significantly higher for the ICU cohort (p<0.05). Average length of stay in hospital was 14.55 days. 28.2% of patients needed ICU admission. 4.9% (n=5) overall died during hospitalisation (all in ICU). Conclusions: In this single-centre study in Dubai, 25% of patients admitted with COVID-19 MESHD also had diabetes MESHD/ prediabetes MESHD. Most diabetes MESHD patients admitted to hospital with COVID-19 MESHD disease were males of Asian origin. 14.6% had new diagnosis of diabetes MESHD/prediabetes on admission. The majority of patients with diabetes MESHD/ prediabetes MESHD and COVID-19 MESHD infection had other important comorbidities (n=76; 73.8%). Only 4 patients had negative COVID-19 MESHD RT-PCR but had pathognomonic changes of COVID-19 MESHD radiologically. Our comprehensive laboratory analysis revealed distinct abnormal patterns of biomarkers that are associated with poor prognosis: Fibrinogen HGNC, D-dimer, Ferritin and CRP HGNC levels were all statistically significantly higher (p<0.05) at presentation in patients who subsequently needed ICU care compared with those patients who remained ward-based. 28.2% overall needed ICU admission, out of which 5 patients died. More studies with larger sample sizes are needed to compare data of COVID-19 MESHD patients admitted with and without diabetes MESHD within the UAE region.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.